Carina Biotech to showcase its LGR5 CAR-T program at the American Association for Cancer Research (AACR) Annual Meeting

Carina has had five abstracts accepted for poster presentations at the AACR Annual Meeting which will take place from April 8 to April 13.

The poster presentations come after Carina’s recent submission of a pre-IND package to the FDA for Carina’s LGR5 CAR-T cell for the treatment of patients with advanced colorectal cancer.

HIGHLIGHTS

  • Five conference abstracts will be presented as poster presentations at AACR in the immuno-oncology and preclinical immunotherapy sessions
  • Four presentations describe preclinical data from Carina’s LGR5-targeted CAR-T cell program, one poster will describe preclinical data from Carina’s ADAM-10 CAR-T program
  • With its LGR5 CAR-T, Carina is progressing towards a first-in-human clinical trial in patients with advanced colorectal cancer
  • Colorectal cancer is the third most commonly diagnosed cancer in Australia and in the United States, and the second leading cause of cancer death in Australia

Carina’s five presentations and their authors are:

  • Session OPO.CL06.01 – Immuno-oncology
    (April 8, 2022, 12:00 PM – 1:00 PM CDT) Abstract online
    5183 – LGR5 CAR-T cells: A novel potential treatment against high grade serous ovarian cancer authors B Wanqi Wang, Veronika Bandara, Noor Lokman, Silvana Napoli, Batjargal Gundsambuu, Martin Oehler, Simon Barry, Carmela Ricciardelli
  • Session OPO.IM02.01 – Preclinical immunotherapy
    (April 8, 2022, 12:00 PM – 1:00 PM CDT) Abstract online
    5575 – Pre-clinical validation of a LGR5-targeting CAR-T against colorectal cancer
    authors Veronika Bandara, Stuart Mills, Emma Thompson, Lih Tan, Batjargal Gundsambuu, Silvana Napoli, Jade Foeng, Dylan McPeake, Justin Coombs, Allison Cowin, Claudine Bonder, Timothy Sadlon, Shaun McColl, Simon Barry
  • Session OPO.IM02.01 – Preclinical immunotherapy
    (April 8, 2022, 12:00 PM – 1:00 PM CDT) Abstract online
    5574 – In vivo characterisation of a novel CAR-T cell therapy directed towards LGR5 for the treatment of colorectal cancer
    authors Dylan McPeake, Timona Tyllis, Jade Foeng, Veronika Bandara, Caitlin Abbott, Batjargal Gundsambuu, Elaheh Rohani-Rad, Silvana Napoli, Timothy Sadlon, Simon Barry, Shaun McColl
  • Session OPO.CL06.01 – Immuno-oncology
    (April 8, 2022, 12:00 PM – 1:00 PM CDT) Abstract online
    5184 – Real-time cytotoxicity assays as a pre-clinical screening tool for LGR5-targeting CAR-T cells for treatment of solid tumors
    authors Emma Thompson, Veronika Bandara, Timothy Sadlon, Batjargal Gundsambuu, Lih Yin Tan, Carmela Ricciardelli, Simon Barry, Claudine Bonder
  • Session OPO.IM02.01 – Preclinical immunotherapy
    (April 8, 2022, 12:00 PM – 1:00 PM CDT) Abstract online
    5505 – ADAM10-targeting CAR-T cells inhibit colon cancer cell growth in vivo
    authors Elaheh Rohani Rad, Jade Foeng, Dylan McPeake, Timona Tyllis, Caitlin Abbott, Veronika Bandara, Silvana Napoli, Batjargal Gundambuu, Timothy Sadlon, Simon Barry, Shaun McColl

 

About LGR5
LGR5 is a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers. In colorectal cancer patients, LGR5+ expression has been correlated with a particularly poor prognosis.

Cancer stem cells are a small sub-population of cells within a tumour with the ability to self-renew, differentiate into the many cell types of a tumour, initiate new tumours, and resist chemotherapy and radiotherapy (leading to relapses).

By targeting cancer stem cells, it is hoped that this therapy will reduce the tumour’s ability to generate new cancer cells, resulting in durable tumour suppression and preventing the relapses that are very common in patients with colorectal cancer.

Carina’s pre-clinical studies of the LGR5-targeted CAR-T cell have shown highly promising results with complete tumour regression and no tumour recurrence. They have also demonstrated impressive tumour access and prolonged CAR-T cell survival.

2022-04-06T10:18:54+09:30April 6th, 2022|News|